Effect of dual growth factor delivery on chondrogenic differentiation of rabbit marrow mesenchymal stem cells encapsulated in injectable hydrogel composites.
An injectable hydrogel composite consisting of oligo(poly(ethylene glycol)fumarate) (OPF) and gelatin microparticles has been developed as a novel carrier system for cells and growth factors. Rabbit marrow mesenchymal stem cells (MSCs) and gelatin microparticles (MPs) loaded with insulin-like growth factor-1 (IGF-1), transforming growth factor-beta1 (TGF-beta1), or a combination of both growth factors were mixed with OPF, a poly(ethylene glycol)-diacrylate crosslinker and the radical initiators ammonium persulfate and N,N,N',N'-tetramethylethylenediamine, and then crosslinked at 37 degrees C for 8 min to form hydrogel composites. Hydrogel composites encapsulating rabbit marrow MSCs and blank MPs served as controls. At day 14, confocal fluorescent images of OPF hydrogels showed a strong aggregation of rabbit marrow MSCs when encapsulated with IGF-1-loaded MPs with or without TGF-beta1-loaded MPs. Quantitative RT-PCR results showed that rabbit marrow MSCs encapsulated with MPs loaded with TGF-beta1 or both TGF-beta1 and IGF-1 had a significant increase in the expression of chondrocyte-specific genes such as collagen type II and aggrecan at day 14 as compared with the control group. Specifically, samples with both TGF-beta1-loaded MPs and IGF-1-loaded MPs exhibited a 121 +/- 20-fold increase of type II collagen gene expression and a 71 +/- 24-fold increase of aggrecan gene expression after 14 days of in vitro culture as compared with controls at day 0. These results suggest that hydrogel composites based on OPF and gelatin microparticles have great potential as carriers for MSCs and multiple growth factors for cartilage tissue engineering applications.
Park
Hansoo
H
Department of Bioengineering, Rice University, MS-142, P.O. Box 1892, Houston, Texas 77251-1892, USA.
Temenoff
Johnna S
JS
Tabata
Yasuhiko
Y
Caplan
Arnold I
AI
Raphael
Robert M
RM
Jansen
John A
JA
Mikos
Antonios G
AG
D000818:Animals; D001672:Biocompatible Materials / Q000737:chemistry / Q000378:metabolism; D002454:Cell Differentiation / Q000502:physiology*; D019902:Chondrocytes / Q000166:cytology / Q000502:physiology*; D020219:Chondrogenesis / Q000502:physiology*; D024043:Collagen Type II / Q000235:genetics / Q000378:metabolism; D004339:Drug Compounding; D016503:Drug Delivery Systems; D005780:Gelatin / Q000737:chemistry / Q000378:metabolism; D006025:Glycosaminoglycans / Q000378:metabolism; D020100:Hydrogels / Q000737:chemistry* / Q000378:metabolism; D007334:Insulin-Like Growth Factor I / Q000378:metabolism / Q000494:pharmacology*; D008422:Materials Testing; D059630:Mesenchymal Stem Cells / Q000166:cytology / Q000502:physiology*; D011091:Polyesters / Q000737:chemistry / Q000378:metabolism; D011092:Polyethylene Glycols / Q000737:chemistry / Q000378:metabolism; D011817:Rabbits; D053773:Transforming Growth Factor beta1 / Q000378:metabolism / Q000494:pharmacology*
D001672:Biocompatible Materials; D024043:Collagen Type II; D006025:Glycosaminoglycans; D020100:Hydrogels; D011091:Polyesters; D053773:Transforming Growth Factor beta1; C469550:oligo(poly(ethylene glycol)fumarate); D011092:Polyethylene Glycols; D007334:Insulin-Like Growth Factor I; D005780:Gelatin